

OniX Hub - Unlocking Animal Health Potential Turning Medical Discoveries into Veterinary Solutions:

From Idea to Market, We Transform Your Assets

Extending Medical Breakthroughs to Companion Animals

Your innovative pharmaceutical breakthrough has already made a difference in human health—but its potential doesn't stop there. Whether your product is already on the market, in development, or undergoing clinical trials, dogs and cats, often considered family members, suffer from many of the same conditions as humans: **osteoarthritis, diabetes, cancer, cardiovascular disease, atopic dermatitis, inflammatory bowel disease, dry eye, and obesity**. OniX Hub provides a proven pathway to bring life-changing treatments to companion animals while maximizing the value of your existing assets.



Every Pharmaceutical Asset Holds Untapped Value

Bringing a drug to market in human medicine requires significant time and resources. But beyond the clinical and commercial success you've achieved, an entirely new market exists—one with strong demand, shorter timelines, and immense growth potential.

Why Explore Companion Animal Health?

- **Rapidly Growing Market:** The global animal health market is projected to reach **\$112.36 billion by 2030**, driven by increased spending on pets and veterinary care.
- **Unmet Medical Needs:** Diseases like **osteoarthritis, diabetes, dementia, chronic kidney disease, inflammatory bowel disease, heart disease, keratoconjunctivitis sicca (dry eye), glaucoma, allergic and atopic dermatitis, fungal and bacterial infections, periodontal disease, chronic gingivostomatitis and cancer** in pets lack advanced, targeted therapies.
- **Faster Regulatory Pathways:** Veterinary drug approval pathways (FDA-Center for Veterinary Medicine (CVM)) are streamlined compared to human approvals,

reducing time to market.

- **Cost-Effective Development:** Companion animal studies require smaller clinical trials with lower associated costs.
- **Pet Owner Demand:** Pet owners are increasingly willing to invest in treatments that improve the health and quality of life of their animals.

How OniX Hub Maximizes the Potential of Your Asset

At OniX Hub, we bridge the gap between human and veterinary medicine, unlocking new value for proven assets while addressing critical health challenges in companion animals.

Our comprehensive process ensures scientific rigor, strategic alignment, and commercial success:

1. Asset Evaluation and Scientific Deep Dive

- Thorough review of your drug's mechanism of action, safety profile, and clinical data.
- Identification of veterinary conditions where your drug could deliver meaningful impact.
- Assessment of feasibility for veterinary formulations and dosing.

2. Strategic Disease Mapping

- Pinpointing diseases in dogs and cats that align with your asset's mechanism.
- Prioritizing conditions with the greatest market need and scientific potential.
- Examples include:
 - **Osteoarthritis:** Chronic joint pain affects **20% of adult dogs**, mirroring human arthritis. Existing therapies are limited, and novel treatments are in demand.
 - **Type 2 Diabetes:** Dogs experience diabetes with pathophysiology remarkably similar to humans, creating opportunities for repurposed glucose management therapies.
 - **Cancer:** Companion animals develop cancers, such as lymphoma and osteosarcoma, that share molecular characteristics with human cancers.
 - **Atopic Dermatitis:** Chronic skin inflammation in pets causes

significant discomfort and parallels human eczema.

- **Dry Eye Disease:** Often underdiagnosed, this condition impairs eye health in dogs and cats, aligning with human ophthalmologic treatments.
- **Obesity and Cardiovascular Disease:** Increasingly common in pets, mirroring human health trends.

3. Companion-Focused Development

- Tailored delivery formats: Treat-based or minimally invasive options for easy administration.
- Focused studies to ensure safety, tolerability, and efficacy in animals.
- Cost-efficient pilot studies and pathways to FDA-CVM approval.

Why Partner with OniX Hub?

OniX Hub combines scientific expertise, strategic market insight, and operational excellence to deliver tangible results:

- **Maximize ROI:** Leverage your existing R&D investment to enter a growing, profitable market.
- **Accelerate Time to Market:** Shorter approval timelines mean faster pathways to commercialization.
- **Expand Your Impact:** Address critical health challenges in animals while showcasing broader applications of your innovation.
- **Enhance Market Position:** Demonstrate leadership by advancing both human and veterinary medicine.

The OniX Hub Advantage: Our Expert Team

Our leadership combines decades of pharmaceutical expertise with deep veterinary medicine experience:

Senior Veterinary Drug Development Consultant

- 30+ years in veterinary and human drug development
- Contributed to US and global approvals of several animal health therapeutics
- International expert in pharmacokinetics, veterinary bioequivalence, antimicrobial PK/PD, and interspecies allometry
- Experience at Elanco (previously Lilly Animal Health) and Pfizer Animal Health
- Specializes in advancing veterinary medicine through innovation and

collaboration

Mr. Martin Dueñas - CEO, OniX Animal Health

- Leads development of innovative nanoformulation delivery systems
- Directs multiple companion animal treatment programs including osteoarthritis, inflammatory bowel disease, diabetes, dementia, dry eye and others
- Established global partnerships across US, EU, Asia, LATAM, and MENA regions
- Built strategic relationships with major pharmaceutical companies including Daiichi Sankyo, Merck, and Eli Lilly
- Expertise in regulatory strategy and clinical development planning with FDA CVM

This combined expertise ensures our partners receive:

- Strategic guidance through regulatory pathways
- Deep scientific understanding of cross-species applications
- Access to established industry networks
- Proven track record in successful drug development and commercialization

Who Benefits from Our Approach?

- Pharmaceutical companies seeking new revenue streams for existing assets.
- Biotech innovators with novel therapeutics ready for broader applications.
- Research institutions with discoveries that can translate to companion animal health.
- Investors looking to diversify opportunities in an underserved market.

Companion Animal Health: A Market of Opportunity

The numbers speak for themselves:

- **70% of U.S. households** have at least one pet, fueling demand for high-quality veterinary care.
- The global companion animal therapeutics market alone is estimated at **\$25 billion** and growing annually.
- Chronic conditions like arthritis, diabetes, and dermatological diseases represent multi-billion-dollar opportunities, with limited therapeutic options available today.

Your Drug's Next Chapter: From Bench to Bark and Meow

With OniX Hub, you can extend your breakthrough's impact, enter a rapidly growing market, and deliver treatments that improve the lives of pets and the families who love them. Let's explore how your innovation can make a difference—and unlock new value—in companion animal health.

Get in Touch

Martin Dueñas

martin@onixhub.com

OniX: The Online Ideas Exchange Hub

Empowering Biotech Innovation, One Ideas, One Asset, One Product at a Time

Follow the [OniX Blog](#) and sign up for the weekly [OniX OnPoint Newsletter](#) and the [OniX OnPoint LinkedIn daily News](#) to stay up-to-date



Connecting Ideas to Opportunities